STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Valentina Cannone, Mark Ledwidge, Chris Watson, Paul M. McKie, John C. Burnett, Kenneth McDonald

Research output: Contribution to journalArticlepeer-review

Abstract

B-type natriuretic peptide (BNP) possesses blood-pressure–lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

Original languageEnglish (US)
Pages (from-to)497-504
Number of pages8
JournalJACC: Basic to Translational Science
Volume6
Issue number6
DOIs
StatePublished - Jun 2021

Keywords

  • B-type natriuretic peptide
  • heart failure
  • rs198389
  • single nucleotide polymorphism
  • STOP-HF Trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure'. Together they form a unique fingerprint.

Cite this